• Mutation; HGNC; HGNC:7133; KMT2D; Simple; p.Gln4118Ter (c.12352C>T); Zygosity=Unspecified (PubMed=30737244).
  
• Mutation; HGNC; HGNC:7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Unspecified (PubMed=23833040; PubMed=30737244).
  
• Mutation; HGNC; HGNC:11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Homozygous; Note=In promoter (PubMed=23833040; PubMed=30737244).
  
• Mutation; HGNC; HGNC:11998; TP53; Simple; p.Gly245Ser (c.733G>A); ClinVar=VCV000012365; Zygosity=Unspecified (PubMed=30737244).
  

PubMed=6220172
Dracopoli N.C., Fogh J.
Polymorphic enzyme analysis of cultured human tumor cell lines.
J. Natl. Cancer Inst. 70:469-476(1983)

PubMed=3518877; DOI=10.3109/07357908609038260
Fogh J.
Human tumor lines for cancer research.
Cancer Invest. 4:157-184(1986)

PubMed=17465858; DOI=10.1089/thy.2006.0246
Lee J.-J., Foukakis T., Hashemi J., Grimelius L., Heldin N.-E., Wallin G., Rudduck C., Lui W.-O., Hoog A., Larsson C.
Molecular cytogenetic profiles of novel and established human anaplastic thyroid carcinoma models.
Thyroid 17:289-301(2007)

PubMed=18713817; DOI=10.1210/jc.2008-1102; PMCID=PMC2582569
Schweppe R.E., Klopper J.P., Korch C.T., Pugazhenthi U., Benezra M., Knauf J.A., Fagin J.A., Marlow L.A., Copland J.A. 3rd, Smallridge R.C., Haugen B.R.
Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification.
J. Clin. Endocrinol. Metab. 93:4331-4341(2008)

PubMed=21868764; DOI=10.1158/1078-0432.CCR-11-0690; PMCID=PMC3229662
Zhao M., Sano D., Pickering C.R., Jasser S.A., Henderson Y.C., Clayman G.L., Sturgis E.M., Ow T.J., Lotan R., Carey T.E., Sacks P.G., Grandis J.R., Sidransky D., Heldin N.-E., Myers J.N.
Assembly and initial characterization of a panel of 85 genomically validated cell lines from diverse head and neck tumor sites.
Clin. Cancer Res. 17:7248-7264(2011)

PubMed=23833040; DOI=10.1210/jc.2013-2383; PMCID=PMC3763971
Landa I., Ganly I., Chan T.A., Mitsutake N., Matsuse M., Ibrahimpasic T., Ghossein R.A., Fagin J.A.
Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease.
J. Clin. Endocrinol. Metab. 98:E1562-E1566(2013)

PubMed=25365311; DOI=10.1210/jc.2014-2359; PMCID=PMC4318896
Garg M., Okamoto R., Nagata Y., Kanojia D., Venkatesan S., Anand M.T., Braunstein G.D., Said J.W., Doan N.B., Ho Q., Akagi T., Gery S., Liu L.-Z., Tan K.-T., Chang W.J., Yang H.H., Ogawa S., Koeffler H.P.
Establishment and characterization of novel human primary and metastatic anaplastic thyroid cancer cell lines and their genomic evolution over a year as a primagraft.
J. Clin. Endocrinol. Metab. 100:725-735(2015)

PubMed=26680454; DOI=10.1186/s12885-015-1955-9; PMCID=PMC4683857
Kasaian K., Wiseman S.M., Walker B.A., Schein J.E., Zhao Y.-J., Hirst M., Moore R.A., Mungall A.J., Marra M.A., Jones S.J.M.
The genomic and transcriptomic landscape of anaplastic thyroid cancer: implications for therapy.
BMC Cancer 15:984.1-984.11(2015)

PubMed=30737244; DOI=10.1158/1078-0432.CCR-18-2953; PMCID=PMC6522280
Landa I., Pozdeyev N., Korch C.T., Marlow L.A., Smallridge R.C., Copland J.A. 3rd, Henderson Y.C., Lai S.Y., Clayman G.L., Onoda N., Tan A.-C., Garcia-Rendueles M.E.R., Knauf J.A., Haugen B.R., Fagin J.A., Schweppe R.E.
Comprehensive genetic characterization of human thyroid cancer cell lines: a validated panel for preclinical studies.
Clin. Cancer Res. 25:3141-3151(2019)